A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Juvenile Idiopathic Arthritis

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03769558

IM101-643

Details and patient eligibility

About

This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept

Enrollment: 264 patients

Sex: All

Ages: 12+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Two diagnoses of JIA (ICD-9 code 714.3x) within 90 days
• Age less than 18 years at the time of second of the two diagnoses
• Index date is the date of initiating treatment with abatacept

Exclusion criteria

• Greater than or equal to 18 years of age

Trial design

264 participants in 1 patient group

JIA patients prescribed abatacept

Treatment:

Other: Non-Interventional